NuCana to Participate in Three Upcoming Investor Conferences

Rhea-AI Summary

NuCana plc (Nasdaq: NCNA) announced participation in several upcoming healthcare conferences. Hugh Griffith (CEO) and Don Munoz (CFO) will present at the Cowen 41st Annual Health Care Conference on March 4, 2021, at 1:30 PM ET, and at the Oppenheimer's 31st Annual Healthcare Conference on March 18, 2021, at 9:20 AM ET. The presentations will be webcast live and available for replay on the company's website. NuCana focuses on developing enhanced cancer therapies using its proprietary ProTide technology, aiming to improve outcomes for patients with various types of cancer.

EDINBURGH, United Kingdom, Feb. 25, 2021 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in the following conferences:

Cowen 41st Annual Health Care Conference
Presentation Date: Thursday, March 4, 2021
Presentation Time: 1:30 PM ET

H.C. Wainwright Global Life Sciences Conference
Dates: March 9-10, 2021

Oppenheimer's 31st Annual Healthcare Conference
Presentation Date: Thursday, March 18, 2021
Presentation Time: 9:20 AM ET

The presentations at the Cowen 41st Annual Health Care Conference and Oppenheimer's 31st Annual Healthcare Conference will be webcast live. Both presentations will be available for replay under “Events & Presentations” in the Investors section of the Company's website at www.nucana.com.

About NuCana

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

Forward-Looking Statements

This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies, including NuTide:121; the Company’s goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission (“SEC”) on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

For more information, please contact:

Hugh S. Griffith
Chief Executive Officer
NuCana plc
Tel: +44 131 357 1111
info@nucana.com

Westwicke, an ICR Company
Chris Brinzey
Tel: +1 339-970-2843
chris.brinzey@westwicke.com

RooneyPartners
Marion Janic
Tel: +1 212-223-4017
mjanic@rooneyco.com

FAQ

When is NuCana's presentation at the Cowen 41st Annual Health Care Conference?

NuCana's presentation at the Cowen 41st Annual Health Care Conference is on March 4, 2021, at 1:30 PM ET.

What is the date for NuCana's presentation at the Oppenheimer's 31st Annual Healthcare Conference?

NuCana's presentation at the Oppenheimer's 31st Annual Healthcare Conference is scheduled for March 18, 2021, at 9:20 AM ET.

Where can I watch NuCana's conference presentations?

NuCana's conference presentations will be webcast live and available for replay on the company's website under the 'Events & Presentations' section.

What technology does NuCana use for cancer treatment development?

NuCana uses its proprietary ProTide technology to develop enhanced cancer therapies aimed at improving patient treatment outcomes.

What are the names of the ProTide drugs in NuCana's pipeline?

NuCana's pipeline includes Acelarin, NUC-3373, and NUC-7738, which are in various stages of clinical development.